Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b studyMatthew S. Davids, Jennifer R. Brown, Haesook T. Kim et al.|The Lancet Haematology|2018Cited by 115
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S. Davids, Jennifer R. Brown, David C. Fisher et al.|The Lancet Haematology|2019Cited by 72
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patientsMatthew S. Davids, Jennifer R. Brown, David C. Fisher et al.|Leukemia|2020Cited by 36
Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL PatientsMatthew S. Davids, Jennifer R. Brown, Haesook T. Kim et al.|Blood|2016Cited by 17
TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib StudyMatthew S. Davids, Jennifer R. Brown, Haesook T. Kim et al.|Blood|2016Cited by 15